<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69830">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02196714</url>
  </required_header>
  <id_info>
    <org_study_id>PT003010-00</org_study_id>
    <nct_id>NCT02196714</nct_id>
  </id_info>
  <brief_title>PK Study of PT003 and PT001 in Japanese Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001 in Japanese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over,
      Single-Center, Phase I, Crossover Study in Healthy Japanese Adult Subjects to Evaluate the
      Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Pharmacokinetic profile of PT003 and PT001</measure>
    <time_frame>24 hour post dose</time_frame>
    <description>The overall pharmacokinetic profile will be assessed based on:
Maximum plasma concentration (Cmax)
Area under the curve from 0 to 12 hours (AUC0 12)
Area under the curve from 0 to time of the last measurable plasma concentration (AUC0 t)
Area under the curve from 0 extrapolated to infinity (AUC0-∞)
Time to maximum plasma concentration (tmax), apparent terminal elimination half-life (t½)
Apparent total body clearance (CL/F),
Apparent volume of distribution (Vd/F)
Terminal elimination rate constant (λz)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Safety of PT003 and PT001</measure>
    <time_frame>24 hours post dose</time_frame>
    <description>The safety of PT003 and PT001 will be assessed based on physical examination, laboratory values and electrocardiogram</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Glycopyrronium and Formoterol Fumarate (GFF) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycopyrronium and Formoterol Fumarate (GFF) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycopyrronium (GP) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycopyrronium (GP) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium and Formoterol Fumarate (GFF) Dose 1</intervention_name>
    <description>Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)</description>
    <arm_group_label>Glycopyrronium and Formoterol Fumarate (GFF) Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium and Formoterol Fumarate (GFF) Dose 2</intervention_name>
    <description>Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)</description>
    <arm_group_label>Glycopyrronium and Formoterol Fumarate (GFF) Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium (GP) Dose 1</intervention_name>
    <description>Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)</description>
    <arm_group_label>Glycopyrronium (GP) Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium (GP) Dose 2</intervention_name>
    <description>Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)</description>
    <arm_group_label>Glycopyrronium (GP) Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Informed Consent Form (ICF) prior to any study related procedures

          -  Male and female first generation Japanese subjects 18 to 45 years, inclusive

          -  Good general health

          -  Medically acceptable contraception for women of child-bearing potential and males
             with female partners of childbearing potential

          -  Clinical labs within normal ranges or determined to be not clinically significant by
             the Investigator

        Exclusion Criteria:

          -  Pregnancy, nursing female subjects, or subjects trying to conceive

          -  Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic,
             pulmonary, hematological, psychiatric, or other medical illness that would interfere
             with participation in this study

          -  History of ECG abnormalities

          -  Cancer not in complete remission for at least 5 years

          -  Clinically significant, symptomatic prostatic hypertrophy

          -  Male subjects with a trans-urethral resection of the prostate or full resection of
             the prostate within 6 months prior to Screening

          -  Clinically significant bladder neck obstruction or urinary retention

          -  Inadequately treated glaucoma

          -  History of an allergic reaction or hypersensitivity to any drug or to any component
             of the formulations used in this study

          -  Subjects with pre-existing anemia and/or iron deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadwick Orevillo</last_name>
    <role>Study Chair</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>October 14, 2014</lastchanged_date>
  <firstreceived_date>July 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
